- Home
- HOOK vs GXAI Comparison
HOOK vs GXAI Comparison
Compare HOOK & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- GXAI
- Stock Information
- Founded
- HOOK 2011
- GXAI 2021
- Country
- HOOK United States
- GXAI United States
- Employees
- HOOK N/A
- GXAI N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- HOOK Health Care
- GXAI
- Exchange
- HOOK Nasdaq
- GXAI Nasdaq
- Market Cap
- HOOK 11.9M
- GXAI 9.7M
- IPO Year
- HOOK 2019
- GXAI 2023
- Fundamental
- Price
- HOOK $0.89
- GXAI $1.14
- Analyst Decision
- HOOK Hold
- GXAI
- Analyst Count
- HOOK 3
- GXAI 0
- Target Price
- HOOK $4.50
- GXAI N/A
- AVG Volume (30 Days)
- HOOK 155.2K
- GXAI 132.2K
- Earning Date
- HOOK 08-11-2025
- GXAI 08-12-2025
- Dividend Yield
- HOOK N/A
- GXAI N/A
- EPS Growth
- HOOK N/A
- GXAI N/A
- EPS
- HOOK N/A
- GXAI N/A
- Revenue
- HOOK $9,351,000.00
- GXAI $27,740.00
- Revenue This Year
- HOOK N/A
- GXAI N/A
- Revenue Next Year
- HOOK N/A
- GXAI N/A
- P/E Ratio
- HOOK N/A
- GXAI N/A
- Revenue Growth
- HOOK N/A
- GXAI 9987.27
- 52 Week Low
- HOOK $0.72
- GXAI $1.00
- 52 Week High
- HOOK $6.00
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- HOOK 19.78
- GXAI 36.51
- Support Level
- HOOK $0.89
- GXAI $1.12
- Resistance Level
- HOOK $0.95
- GXAI $1.28
- Average True Range (ATR)
- HOOK 0.06
- GXAI 0.06
- MACD
- HOOK -0.01
- GXAI -0.01
- Stochastic Oscillator
- HOOK 7.11
- GXAI 7.14
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.